An observational study in Cytopenia, sponsored by Royal Marsden NHS Foundation Trust. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-28.
Sponsored by Royal Marsden NHS Foundation Trust · Observational
10% of the cases referred to the specialist diagnostic haemato-pathology service at RMH are for cytopenias.
The hypothesis to be tested is that a proportion of patients with idiopathic cytopenias have mutations in myelodysplasic syndrome (MDS)-associated genes. The investigators will sequence a panel of known MDS-associated genes in patient material (bone marrow and blood) that is sent routinely to the diagnostic service where conventional techniques have failed to establish a clear diagnosis. 200 patients with idiopathic cytopenia will be followed up to determine their survival, blood counts and development of acute leukaemia and other haematological malignancies. The clinical outcomes will be correlated with any mutations detected.
Patients with cytopenias will be identified by their local District General Consultant haematologist and consent obtained. A bone marrow sample will be sent to RMH as per usual diagnostic pathway.
Once received at the RMH, an aliquot will be frozen down for sequencing by the Molecular Pathology lab. Only those cases of cytopenia without a specific diagnosis will be the focus of this study.
Results will be fed back to referring consultants with caveats regarding significance.
Patients will undergo telephone follow up and data will also be provided by local consultants.
The investigators will look at overall survival, development of haematological malignancies and full blood count. This will occur annually.
87 studies on the registry are indexed under Cytopenia; 24 are open to participants now.
This study's planned enrollment of 285 is above the median of 200 across 20 observational studies indexed under Cytopenia.
Browse Cytopenia studies →Royal Marsden NHS Foundation Trust is the lead sponsor of 272 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Blood and bone marrow samples are routinely sent to RMH from District General Hospitals for special tests to make a diagnosis for patients with blood problems.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Bone marrow aspirate
Percentage of patients with idiopathic cytopenia with a mutation
Time frame: 5 years
Plan to share: No
Started May 2017 (actual). Primary completion is estimated for Apr 2021, 47 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust →